Wang, Yongjun NA |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
| Completed | 3 | 1552 | RoW | rhPro-UK, rt-PA | Tasly Biopharmaceuticals Co., Ltd. | Acute Ischemic Stroke | 03/24 | 03/24 | | |
NCT04984577: Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke |
|
|
| Suspended | 2 | 240 | RoW | Compound Edaravone Injection-Low dose, Compound Edaravone Injection-High dose, Edaravone Injection, Placebo injection | Nanjing Yoko Biomedical Co., Ltd. | Acute Ischemic Stroke | 12/26 | 12/26 | | |
NCT06202378: Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke |
|
|
| Active, not recruiting | 2 | 270 | RoW | 3 ampoules of SHPL-49 Injection, 6 ampoules of SHPL-49 Injection, 0.9% Sodium Chloride Injection | Shanghai Hutchison Pharmaceuticals Limited, Beijing Tiantan Hospital | Acute Ischemic Stroke | 12/24 | 12/25 | | |
NCT05745311: Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke |
|
|
| Not yet recruiting | 2 | 240 | NA | The KPCXM18 injection, Placebo | Kunming Pharmaceuticals, Inc. | Acute Ischemic Stroke | 05/24 | 07/24 | | |
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke |
|
|
| Recruiting | 2 | 300 | RoW | LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Acute Ischemic Stroke | 04/25 | 07/25 | | |
NCT05200728: The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers |
|
|
| Completed | 1 | 68 | RoW | SIM1910-09, AER-271, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Acute Ischemic Stroke, Cerebral Edema | 03/23 | 03/23 | | |
Peng, Yuming |
No trials found |
Liu, Weiming |
No trials found |
Wu, Liang |
No trials found |